期刊
CANCERS
卷 13, 期 10, 页码 -出版社
MDPI
DOI: 10.3390/cancers13102465
关键词
alkylator; myeloma; melflufen; melphalan; bendamustine; cyclophosphamide
类别
Alkylating drugs have been a standard treatment for multiple myeloma for decades, and even in the era of targeted treatment, they continue to play a significant role, with new alkylators continuing to be developed and introduced to the market.
Simple Summary In this review we have summarized the history, the current use, and the future possibilities of alkylator treatment in multiple myeloma. Alkylators have for decades been part of the standard of care of myeloma treatment, but still new alkylators and new use of old alkylators are making its way into myeloma guidelines of today. A large number of novel treatments for myeloma have been developed and approved; however, alkylating drugs continue to be part of standard regimens. Additionally, novel alkylators are currently being developed. We performed a non-systematized literary search for relevant papers and communications at large conferences, as well as exploiting the authors' knowledge of the field, to review the history, current use and novel concepts around the traditional alkylators cyclophosphamide, bendamustine and melphalan and current data on the newly developed pro-drug melflufen. Even in the era of targeted treatment and personalized medicine, alkylating drugs continue to be part of the standard-of-care in myeloma, and new alkylators are coming to the market.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据